GLSI:NASDAQGreenwich LifeSciences, Inc. Analysis
Data as of 2026-09-27 - not real-time
$18.22
Latest Price
9/10Risk
Risk Level: High
Executive Summary
The moving-average structure behind Greenwich LifeSciences, Inc. is neutral at $18.22, with no clear ordering between short and long averages. The last 30 days have gained 11.2%. Momentum indicators put RSI at 56.2 (neutral) with MACD reading bullish. Recent trading has carved out support near $14.25 and resistance around $20.31.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 212.8% above where the shares trade now.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 100.7%, a beta of 3.07 and a maximum drawdown of 61.9%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
This one splits by horizon — hold in the near term, sell further out, at 4/10 long-term conviction.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 212.8% above where the shares trade now.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 100.7%, a beta of 3.07 and a maximum drawdown of 61.9%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
This one splits by horizon — hold in the near term, sell further out, at 4/10 long-term conviction.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 2/10
Key Factors
- Trading below the 200-day average of 21.72
- MACD momentum is positive
- 30-day price change of +11.2%
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- Trading below the 200-day average of 21.72
- Analyst targets imply +212.8% versus the current price
- 30-day volatility of 100.7%
Long Term
> 3 yearsCautious
Model confidence: 4/10
Key Factors
- Analyst targets imply +212.8% versus the current price
- Negative return on equity of -986.3%
- Negative free cash flow
Key Metrics & Analysis
Financial Health
P/E Ratio-22.2
ROE-986.32%
ROA-235.98%
P/B Ratio85.9
Op. Cash Flow$-12488140
Free Cash Flow$-3343123
Industry P/E30.5
Technical Analysis
TrendNeutral
RSI56.2
Support$14.25
Resistance$20.31
MA 20$16.57
MA 50$15.85
MA 200$21.72
MACDBullish
VolumeIncreasing
Fear & Greed Index94.88
Valuation
Target Price$57.00
Upside/Downside212.84%
GradeFair
TypeGrowth
Risk Assessment
Beta3.07
Volatility100.73%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.